Company Description
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control.
It offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption, as well as Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice after one to two breeding cycles following consumption.
The company also provides teleconsulting and technical advisory services. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
| Country | United States |
| Founded | 2004 |
| IPO Date | Dec 8, 2016 |
| Industry | Specialty Chemicals |
| Sector | Materials |
| Employees | 23 |
| CEO | Joel Fruendt |
Contact Details
Address: 777 West Pinnacle Peak Road, Suite B104 Phoenix, Arizona 85027 United States | |
| Phone | 928 779 4143 |
| Website | senestech.com |
Stock Details
| Ticker Symbol | SNES |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680378 |
| CUSIP Number | 81720R208 |
| ISIN Number | US81720R5054 |
| Employer ID | 20-2079805 |
| SIC Code | 2870 |
Key Executives
| Name | Position |
|---|---|
| Joel L. Fruendt | Chief Executive Officer, President and Director |
| Thomas C. Chesterman M.B.A. | Executive Vice President, Chief Financial Officer, Treasurer and Secretary |
| Robert Blum | Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | D | Notice of Exempt Offering of Securities |
| Aug 12, 2025 | SCHEDULE 13G/A | Filing |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jul 18, 2025 | EFFECT | Notice of Effectiveness |
| Jul 18, 2025 | 424B3 | Prospectus |
| Jul 14, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 11, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 10, 2025 | 8-K | Current Report |